Fotantinib (Fotantinib) detailed instructions and instructions for use

Fostamatinib, also known as Fostamatinib, is an oral spleen tyrosine kinase (SYK) inhibitor. It was first developed by Rigel Pharmaceuticals and later co-promoted by AstraZeneca. The drug has been approved for marketing in some European and American countries and is used to treat chronic immune thrombocytopenia (ITP) and other diseases in adults. Fostatinib has shown good efficacy in fighting immune diseases by targeting immune signaling pathways. The following is a detailed analysis of the instructions and usage instructions for this drug.

1. [Indications]

Fostatinib is mainly used to treat chronic immune thrombocytopenia (ITP) in adults, especially in patients who have an inadequate response to glucocorticoids, immunoglobulins, or splenectomy. ITPIt is an autoimmune disease in which patients produce antibodies that attack their own platelets, causing bleeding tendencies. Fostatinib blocks antibody-mediated platelet clearance by inhibiting SYK, thereby increasing peripheral platelet levels and reducing the risk of bleeding.

In addition, in clinical studies, fostatinib has also shown potential efficacy in immune-mediated diseases such as rheumatoid arthritis and IgA nephropathy. However, the main approved indication is still chronic ITP.

2. [Usage and Dosage]

The recommended starting dose is:100 mg taken orally twice daily.

If the platelet count does not reach the target after 4 weeks of treatment (for example, it is still lower than 50×1 0⁹/L) and the patient tolerates treatment, the dose can be increased to 150 mg twice daily.

If serious adverse reactions occur, such as abnormal liver function, high blood pressure, etc., you should consider reducing the dose or suspending the medication. The specific adjustments should be based on the doctor's evaluation.

The medicine should be swallowed whole and should not be broken or chewed. Keep the medication time as fixed as possible to help maintain stable blood concentration. Can be taken with or without food.

3. [Taboos and Precautions]

Abnormal liver function: Fostatinib is metabolized mainly through the liver. Patients with abnormal liver function should use it with caution and the dose may need to be adjusted.

Risk of hypertension: It is common for blood pressure to rise during treatment. It is recommended to monitor blood pressure regularly and combine antihypertensive drugs when necessary.

Gastrointestinal reactions: Some patients may experience gastrointestinal discomfort such as diarrhea and nausea. Mild symptoms can usually resolve on their own. In severe cases, the dose should be suspended or adjusted.

Hematological examination: Platelet count and blood routine should be monitored every two weeks in the early stage of treatment. After the therapeutic effect is stable, the testing period can be extended.

Drug interactions: Fostatinib is metabolized by hepatic enzymes. When used together with CYP3A4 inhibitors or inducers, its blood concentration may be affected. Please consult your doctor before use.

4. [Common adverse reactions]

The adverse reactions of fostatinib are relatively controllable, most are mild to moderate, and common ones include:

Hypertension (approximately28%): Regular monitoring is required, and in severe cases, antihypertensive treatment may be combined.

Diarrhea and nausea: It may affect appetite. It is recommended to replenish water and pay attention to a light diet.

Elevated liver enzymes (ALT/AST): Usually transient, liver function needs to be monitored closely.

Fatigue: Some patients experience mild fatigue after taking the drug.

Rare but serious adverse events that require attention include severe liver injury, neutropenia, etc. If abnormal symptoms occur, seek medical attention immediately.

5. [Drug use during pregnancy and lactation]

There are insufficient data on the safety of fostatinib during pregnancy or breastfeeding. Animal experiments show that it may affect embryonic development, so it is contraindicated by pregnant women. Women of childbearing age should take effective contraceptive measures while taking the drug. If used during lactation, the pros and cons should be weighed, and breastfeeding should be suspended if necessary.

6. [Storage conditions and validity period]

This product should be stored below 25°C (room temperature) to avoid high temperature and humidity.

Medicines must be kept sealed and out of reach of children.

The validity period is generally 2-3 years. Please use it within the validity period marked on the packaging. Please do not dispose of expired drugs by yourself. They should be disposed of according to the drug recycling method.

7. [Patient usage guidance and suggestions]

Take the medication as directed by your doctor: Fostatinib is a prescription drug. Please take it strictly according to the doctor's instructions. Do not stop the medication or change the dosage at will.

Regular review: During the treatment process, blood routine, liver function and blood pressure need to be checked regularly, and the efficacy and adverse reactions should be evaluated in a timely manner.

Pay attention to diet and lifestyle: During treatment, you should eat a light diet, drink plenty of water, take rest, and avoid infection or trauma.

Treatment requires patience: some patients respond slowly initially, and it is recommended to continue treatment for at least 8-12 weeks before evaluating the efficacy.

Fostatinib brings a new treatment option to patients with chronic immune thrombocytopenia, especially in patients who are ineffective or intolerant to traditional treatments, showing good efficacy. Although adverse reactions need to be closely monitored during medication, the overall safety profile is good. In the future, as clinical research for more indications advances, fostatinib is expected to play a role in more immune-related diseases. During use, patients should have regular follow-up visits to ensure that the treatment is safe, effective and sustainable.

Reference materials:https://www.drugs.com/